Pathogen Reduction of Plasma
Authors: not saved
Abstract:
This article doesn't have abstract
similar resources
Methylene Blue Based Device for Pathogen Reduction in Human Plasma
Abstract Background Despite improvement in safety of plasma transfusion some virus transmission still remains a problem. So as World Health Organization (WHO) recommends, many countries developed Pathogen Reduction Technologies (PRT) to inactivate pathogens, in plasma components. The Methylene Blue (MB) based methods is one of the most universal one. The purpose of this research was, produce...
full textUVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma.
Besides the current efforts devoted to microbial risk reduction, pathogen inactivation technologies promise reduction of the residual risk of known and emerging infectious agents. A novel pathogen reduction process for platelets, the THERAFLEX UV-Platelets system, has been developed and is under clinical evaluation for its efficacy and safety. In addition, proof of principle has been shown for ...
full textPathogen reduction of blood components and plasma derivatives
The pathogen safety of plasma derivative and labile blood components has been dramatically enhanced over the last 25 years through the implementation of nucleic acid testing (NAT) technologies that effectively screen out units with high virus titers. Additionally, the incorporation of pathogen inactivation (PI) and removal steps into the manufacturing processes of plasma-derived medicinal produ...
full textSAFETY OF BLOOD AND PLASMA DERIVATIVES: PATHOGEN REDUCING TECHNOLOGIES
ABSTRACT Human blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. Despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood transfusion. In this article various measures and technologies that can be applied in...
full textMethylene Blue Based Device for Pathogen Reduction in Human Plasma
BACKGROUND Despite improvement in safety of plasma transfusion some virus transmission still remains a problem. So as World Health Organization (WHO) recommends, many countries developed Pathogen Reduction Technologies (PRT) to inactivate pathogens, in plasma components. The Methylene Blue (MB) based methods is one of the most universal one. The purpose of this research was, produce a device th...
full textMy Resources
Journal title
volume 3 issue None
pages 0- 0
publication date 2011-05
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023